Advancement of PI3 kinase inhibitor combination therapies for PI3K-aberrant chordoma

MEH Neal, NL Michmerhuizen… - … Surgery Part B: Skull …, 2022 - thieme-connect.com
Objectives Targeted inhibitors of the PI3 kinase (PI3K) pathway have shown promising but
incomplete antitumor activity in preclinical chordoma models. The aim of this study is to …
被引用次数：2 相关文章

Advancement of PI3 Kinase Inhibitor Combination Therapies for PI3K-Aberrant Chordoma.

HN ME, NL Michmerhuizen, KJ Kovatch… - … surgery. Part B, Skull …, 2020 - europepmc.org
Objectives Targeted inhibitors of the PI3 kinase (PI3K) pathway have shown promising but
incomplete antitumor activity in preclinical chordoma models. The aim of this study is to …

Advancement of PI3 Kinase Inhibitor Combination Therapies for PI3K-Aberrant Chordoma

MEH Neal, NL Michmerhuizen… - … surgery. Part B …, 2020 - pubmed.ncbi.nlm.nih.gov
Objectives Targeted inhibitors of the PI3 kinase (PI3K) pathway have shown promising but
incomplete antitumor activity in preclinical chordoma models. The aim of this study is to …
[HTML] nih.gov

[HTML][HTML] Advancement of PI3 Kinase Inhibitor Combination Therapies for PI3K-Aberrant Chordoma

MEH Neal, NL Michmerhuizen, KJ Kovatch… - … Surgery. Part B, Skull …, 2022 - ncbi.nlm.nih.gov
Objectives Targeted inhibitors of the PI3 kinase (PI3K) pathway have shown promising but
incomplete antitumor activity in preclinical chordoma models. The aim of this study is to …